Revvity Inc. stock holds near 52-week high as valuation debate intensifies

Revvity Inc. stock is trading close to its 52-week high around early September 2026, while analysts and valuation models send mixed signals on how much upside remains for the life-science tools company.

Revvity Inc. stock (ISIN US76155R1086) is trading close to its recent highs, with the shares closing at 130.94 USD on September 2, 2026 on the New York Stock Exchange according to MarketScreener data, leaving the life-science tools group in focus for investors assessing further upside potential.

Stock price pushes toward 52-week peak

According to a valuation review on GuruFocus, Revvity shares rose 3.4% on September 2, 2026 to 130.94 USD.

The same analysis notes that over the past 52 weeks the stock has traded between a low of 81.22 USD and a high of 131.75 USD, meaning the latest close leaves Revvity less than 1 USD below its 52-week high and more than 60% above the low point.

GuruFocus estimates Revvity's intrinsic value at 117.53 USD per share based on its GF Value model as of September 2, 2026, implying the current price is about 11.4% above that fair-value estimate and flagging the stock as overvalued on this metric.

Analyst stance remains constructive

A separate note summarized by MarketScreener on September 3, 2026 reports that Baird has reiterated a positive opinion on Revvity, with the stock last quoted again at 130.94 USD as of the New York close on September 2, 2026.

The same overview indicates that at this closing level the shares were up 3.63% on a year to date basis and about 35.34% over the past 12 months, underlining that Revvity has significantly outperformed many broader indices over that period.

For investors, this combination of a constructive analyst stance and a strong double digit 12-month gain, while the share price trades close to its 52-week high, makes the entry point central to the investment case.

Valuation signals diverge

While the GF Value model suggests that Revvity is trading 11.4% above its estimated fair value of 117.53 USD per share as of September 2, 2026, the same GuruFocus analysis assigns the company a GF Score of 77 out of 100, indicating generally solid fundamental and momentum characteristics even at this higher valuation.

In addition, a separate article on Yahoo Finance dated September 3, 2026 argues that the stock looks roughly fairly valued on a discounted cash flow basis, even if it appears more demanding when measured on traditional earnings multiples.

For shareholders, this divergence between cash flow based fair value estimates and earnings multiples makes upcoming quarterly results and any guidance changes particularly important catalysts for reassessing Revvity's risk reward profile.

Diagnostics and life-science tools as growth drivers

Revvity Inc. focuses on diagnostics, life-science research tools and related services, supplying instruments, reagents and software used by pharmaceutical companies, diagnostics laboratories and academic institutions.

These activities give the company exposure to long term demand drivers such as expanding pharmaceutical R and D pipelines, growth in genetic and molecular testing, and higher testing volumes in emerging markets.

Historically, life-science tools providers have often been able to pair mid single digit to double digit organic revenue growth with high margins, but the current valuation debate around Revvity underscores that investors are scrutinizing how consistently such growth can be delivered from the current earnings base.

Revvity Inc. stock and investor takeaway

Based on the latest available market data, Revvity Inc. stock closed at 130.94 USD on the New York Stock Exchange on September 2, 2026, only marginally below its 52-week high of 131.75 USD and significantly above the 52-week low of 81.22 USD cited by GuruFocus, highlighting how strongly the shares have recovered over the past year.

With some valuation models indicating that the stock trades about 11.4% above estimated fair value and others seeing it closer to fairly valued on a cash flow basis, positioning in Revvity now largely depends on how investors judge the company's ability to sustain its growth trajectory and profitability in the coming reporting periods.

Revvity Inc. stock at a glance

• Company: Revvity Inc.
• ISIN: US76155R1086
• Ticker: RVTY
• Trading venue: NYSE
• Price (as of September 2, 2026): 130.94 USD
• Market capitalization: not specified in available sources
• Sector / Industry: Health care / Life-science tools and diagnostics
• Index membership: S and P 500